Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | CPA1 | P15085 | 2/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.49 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30052708 | 0.93 | TERT (0.49) | MMEACECPA1ACE2TERT | |
| SCHEMBL30563311 | 0.87 | TERT (0.40) | MMEACECPA1ACE2TERT | |
| SCHEMBL29886647 | 0.86 | MME (0.59) | MMEACECPA1ACE2TERT | |
| SCHEMBL15663557 | 0.86 | MME (0.62) | MMEACECPA1ACE2TERT | |
| SCHEMBL8723097 | 0.86 | MME (0.62) | MMEACECPA1ACE2TERT | |
| SCHEMBL8723093 | 0.86 | MME (0.62) | MMEACECPA1ACE2TERT | |
| SCHEMBL30051655 | 0.85 | MME (0.54) | MMEACECPA1ACE2TERT | |
| SCHEMBL29448562 | 0.85 | MME (0.46) | MMEACECPA1ACE2TERT | |
| SCHEMBL31257047 | 0.82 | MME (0.43) | MMEACECPA1ACE2TERT | |
| SCHEMBL31326252 | 0.82 | TERT (0.41) | MMEACECPA1ACE2TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12257323-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11865192-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-3436012-B1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES INC (US) | 2023-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | MMP8, CD68, ELANE | MME 540/4885ACE 258/4885CPA1 318/4885 |
| US-11865192-B2 | Modified wound dressings | MMP8, CD68, ELANE | MME 540/4885ACE 258/4885CPA1 318/4885 |
| US-12257323-B2 | Modified wound dressings | MMP8, CD68, ELANE | MME 540/4885ACE 258/4885CPA1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.